Algert Global LLC Protagonist Therapeutics, Inc Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Algert Global LLC holds 115,679 shares of PTGX stock, worth $4.8 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

115,679

Previous 152,079 23.93%

Holding current value

$4.8 Million

Previous $5.27 Million 1.21%

% of portfolio

0.14%

Previous 0.18%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$33.72 - $47.33 $1.23 Million - $1.72 Million	-36,400 Reduced 23.93%	115,679 $5.21 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $104,459 - $147,412	4,236 Added 2.87%	152,079 $5.27 Million
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $1.57 Million - $2.32 Million	72,083 Added 95.15%	147,843 $4.28 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $41,166 - $68,679	2,930 Added 4.02%	75,760 $1.74 Million
Q3 2023 Nov 13, 2023	BUY	$16.68 - $23.66 $760,608 - $1.08 Million	45,600 Added 167.46%	72,830 $1.22 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $111,183 - $181,151	6,170 Added 29.3%	27,230 $752,000
Q1 2023 May 12, 2023	SELL	$10.78 - $25.38 $680,347 - $1.6 Million	-63,112 Reduced 74.98%	21,060 $484,000
Q4 2022 Feb 13, 2023	BUY	$7.36 - $11.17 $97,446 - $147,890	13,240 Added 18.67%	84,172 $918,000
Q3 2022 Nov 15, 2022	SELL	$7.86 - $11.71 $134,916 - $201,002	-17,165 Reduced 19.48%	70,932 $598,000
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $450,286 - $1.63 Million	63,780 Added 262.29%	88,097 $697,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $567,558 - $877,357	24,317 New	24,317 $576,000
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $146,014 - $256,961	-15,517 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $45,169 - $65,188	5,030 Added 47.96%	15,517 $188,000
Q1 2019 May 01, 2019	SELL	$6.5 - $13.77 $23,101 - $48,938	-3,554 Reduced 25.31%	10,487 $132,000
Q4 2018 Feb 01, 2019	SELL	$6.3 - $10.44 $191,746 - $317,751	-30,436 Reduced 68.43%	14,041 $94,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $50,672 - $83,661	-7,430 Reduced 14.31%	44,477 $458,000
Q2 2018 Aug 02, 2018	BUY	$5.99 - $9.1 $310,922 - $472,353	51,907 New	51,907 $349,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.04B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Protagonist Therapeutics, Inc Transaction History